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Epidermal growth factor receptor (EGFR) is the target of several clinically approved tyrosine kinase
inhibitor (TKI) drugs including gefitinib and erlotinib in the treatment of cancer. Multiple mechanisms have
been implicated in the clinical features of these drugs. However, little is known about the molecular
mechanism of action of these drugs at the whole cell level. Here we applied a label-free biosensor-enabled
dynamic mass redistribution (DMR) assay to assess the molecular mechanism of action of three EGFR
inhibitors, gefitinib, erlotinib and AG1478, to alter the EGFR signaling in A431 and HT-29, two native
cancer cell lines expressing the EGFR. The whole-cell DMR assays with the persistent inhibitor treatment
showed that all inhibitors dose-dependently inhibited the EGFR signaling in both cell lines, but generally
displayed higher potency in A431 than HT-29 cells. The DMR assays with the inhibitor washout showed
that the washout unexpectedly increased the potency of gefitinib and AG-1478 to inhibit the EGFR
signaling in A431, but slightly decreased the potency of all three inhibitors in HT29. The DMR assays under
microfluidics showed that the removal of the inhibitors using buffer perfusion resulted in a time-
dependent recovery of EGF signaling that is slower in A431 than HT-29 cells. In contrast, DMR assays under
microfluidics showed that the removal of reversible competitive antagonists led to the full recovery of the
signalling of two distinct G protein-coupled receptors (GPCRs), the b2-adrenergic receptor in A431 and the
GPR35 in HT-29 cells. Together, our results suggest that for EGFR inhibitors their uptake and retention,
rather than binding kinetics, dominate their label-free cell phenotypic efficacy; however, for GPCR
antagonists the binding characteristics are critical to the inhibitory effects. This study also implicates the
potential of DMR assays under different simulation conditions for elucidating the cell phenotypic
pharmacology, in particular transporter-related drug resistance, of kinase inhibitor drugs.
Introduction
The epidermal growth factor receptor (EGFR) family of
receptor tyrosine kinases consists of four members including
EGFR, erbB2 (HER2), erbB3 and erbB4. With the exception of
HER2, all bind to receptor-specific ligands. Agonist binding
facilitates either homo- or hetero-dimerization between
different receptors of the EGFR family, leading to the
activation of a multitude of signaling cascades via their
tyrosine kinase activity.1–3 EGFR plays a critical role in the
control of cell proliferation, differentiation, and survival.
Abnormalities in signaling of the EGFR pathway have been
found in a wide range of cancers, including lung, breast, and
colon cancers. EGFR activation in many epithelial malignan-
cies has been shown to be a result of overexpression of ligands
and receptors, EGFR gene gain, or activating mutations; and
EGFR activation appears important in tumour growth and
progression.4–6 The inhibitors of EGFR and/or HER2 signaling
have been extensively evaluated in the clinic and shown to
have therapeutic benefits for certain cancer patients.6–8 The
marketed EGFR antagonist drugs to date include monoclonal
antibodies, such as cetuximab and panitumumab, and small
molecule tyrosine kinase inhibitor (TKI) drugs, such as
erlotinib, gefitinib, lapatinib and icotinib, that target the
catalytic domain of the EGFR.6–9
Enormous efforts have been attempted to elucidate the
molecular mechanism(s) of action underlining the clinical
features including efficacy,4–7 resistance10–12 and safety13
profiles of EGFR inhibitor drugs. The clinical efficacy of these
inhibitors has been attributed to their ability to inhibit the
activation and signaling pathways of overexpressed EGFR or its
activating mutants via reversible competitive binding with
MgATP to the intracellular protein tyrosine kinase domain of
the receptor.4–7 Factors that contribute to the resistance
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include expression of activating mutants of EGFR downstream
signaling cascades such as K-RAS,11 the expression of
inhibitor-insensitive activating receptor mutants,12 overexpres-
sion of drug transporters such as breast cancer resistance
protein (BCRP/ABCG2),14 or residues of cancer stem cells.15
Recently, the binding kinetics, in particular drug residence
time (reciprocal of the off rate), have been implicated in the in
vitro and in vivo efficacy and other profiles of drugs for many
classes of targets.16–20 For EGFR TKIs, both on and off rates of
the binding have been postulated to impact their efficacy to
block EGFR signaling.21–23 However, little is known about the
molecular mechanism of action of the EGFR inhibitors to
block receptor signaling in real time and at the whole cell
signaling network level.
Here we report an assessment of the molecular mechanism
of action of three inhibitors to inhibit the EGFR signaling at
the whole cell level using label-free biosensor-enabled
dynamic mass redistribution (DMR) assays under different
assay conditions. DMR assay is a whole cell phenotypic assay
that offers a holistic and real-time view of the drug action
through the receptor in native cells.24–27 Using DMR assays we
showed that the uptake and retention of these TKI inhibitors
are more important to their whole cell efficacy for inhibiting
EGFR signaling than their binding kinetics.
Materials and methods
Materials
Epidermal growth factor (EGF) was obtained from Bachem
(Torrance, CA, USA). AG1478, CID 2745687, gefitinib (Iressa),
isoprotenerol, sotalol, and zaprinast were obtained from
Tocris Chemical Co. (St. Louis, MO, USA). Erlotinib (Tarceva)
was obtained from Santa Curz Biotechnology Inc. (Santa Curz,
CA, USA). Polydimethylsiloxane (PDMS) was obtained from
Dow Chemical (Midland, MI, USA). Epic1 384-well biosensor
cell culture compatible microplates were obtained from
Corning Incorporated (Corning, NY, USA). Human colorectal
adenocarcinoma HT-29 and human epidermoid carcinoma
A431 cell lines were obtained from American Type Cell Culture
(Manassas, VA, USA).
Cell culture
The HT-29 cells were cultured in McCoy’s 5a Medium Modified
supplemented with 10% fetal bovine serum, 4.5 g L21 glucose,
2 mM glutamine, and antibiotics at 37 uC under air/5% CO2.
The A431 cells were cultured using Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum, 4.5 g L21 glucose, 2 mM glutamine, and antibiotics in a
humidified 37 uC/5% CO2 incubator.
For DMR assays in microplate, the cells were cultured in
Epic1 biosensor cell culture compatible microplates for one
day. The initial seeding density was 25 000 and 32 000 cells
well21 for A431 and HT-29, respectively. After culture for y20
h the cells reached a confluency of y95%. A431 cells were
further subject to overnight starvation under serum-free
medium.
For DMR assays under microfluidics the cells were cultured
in a PDMS-based microfluidic biosensor device. The micro-
fluidic device was fabricated using a method described
previously.28,29 Briefly, a PDMS pre-polymer solution contain-
ing a mixture of PDMS oligomers and a reticular agent with
10 : 1 mass ratio (Sylgard 184 Kit, Dow Corning Corp.,
Midland, MI, USA) was cast onto patterned silicon wafers,
and cured at room temperature for about 24 h to minimize
shrinkage after curing. Afterwards, the PDMS replicas
obtained were punched to generate inlet and outlet holes,
and then aligned and reversibly bonded onto the top of the
biosensor inserts. The microfluidic biosensor device has a 3 6
4 array of functional RWG biosensors, each having a
dimension of 2 6 2 mm, and a 3 6 4 array of microfluidic
chambers, each having three inlets and one outlet. The
distance from an inlet to the outlet is 9 mm, the central width
of the chamber 5 mm. To ensure appropriate cell culture and
minimize the effect of any non-specific absorption of ligand
molecules to the top PDMS surface of the microchamber on
the cells, the height of the microchannel was set to be 200 mm.
The total volume required to fill up a chamber is 6 ml. Before
cell culture, the device, tubing (Tygon S-54-HL, Saint-Gobain
Performance Plastics, Akron, OH, USA) and syringes (500 ml,
gas tight 1700 series, Hamilton, Reno, NV, USA) were sanitized
with 70% ethanol and dried using nitrogen flow. Immediately,
4 6 104 cells suspended in 6 ml of the culture medium were
injected into each chamber. Cells were allowed to seed via 30
min incubation at room temperature. Tubing was then
plugged into the microchamber inlets and was connected to
syringes connecting to a syringe pump (Model: SP230IW;
World Precision Instruments, Sarasota, FL, USA). The cells
were then cultured at 37 uC/5% CO2 with a continuous
perfusion of the culture media at a flow rate of 5 ml h21. After
culture for y20 h the cells reached a confluency of about 95%.
Instruments
Two distinct biosensor systems, Epic1 and a high resolution
version of Epic1 BT (Corning Incorporated), were used.
Epic1 system is a wavelength interrogation reader system.30
This system consists of a temperature-control unit, an optical
detection unit, and an on-board liquid handling unit operated
by robotics. The detection unit is centred on integrated fibre
optics which scans across the plate with a temporal resolution
of 15 s. The high resolution Epic1 BT system is a swept
wavelength interrogation system which uses a light beam from
a swept tunable light source to illuminate the 3 6 4 biosensor
array within a 384 well microplate biosensor bottom insert,
and a high speed complementary metal-oxide semiconductor
(CMOS) digital camera to record the escaped and reflected
resonant lights with a spatial resolution of 12 mm.28,29,31 The
tunable light source sweeps the wavelength range from 825 to
840 nm in a stepwise fashion. A total of 150 spectral images
were acquired within a single sweeping cycle (3 s), and were
then processed into sensor resonance wavelength or DMR
image in real time with a temporal resolution of 3 s. The
Epic1 system is tailored for resonant waveguide grating
(RWG) biosensors in microplate, and is a bulky standalone
system compatible to high throughput screening. The Epic1
BT system is flexible in terms of biosensor footprint and



















































operational procedure, and has a small footprint which can be
placed inside cell culture incubators.
The RWG biosensor employs a surface bound evanescent
wave, an electromagnetic field created by the total internal
reflection of resonant light at a solution-surface interface
which typically extends a short distance (y150 nm) into the
solution or adherent cells, to monitor in real-time ligand-
induced dynamic redistribution of cellular matters within the
bottom portion of cells.24,25 The DMR signal is often recorded
as a time-series of the shifts (in picometers, pm) of the
biosensor resonance wavelength.27 The resonance wavelength
is a function of the local refractive index at or near the sensor
surface, which is proportional to the mass density and
distribution of biomaterials within the cells.24 Receptor
signalling is known to result in protein trafficking, microfila-
ment remodelling, cell adhesion alterations, and morphologi-
cal changes of cells, all of which can lead to significant mass
redistribution, thus contributing to the DMR signal obtained.
Thus, a ligand-induced DMR signal is an integrated cellular
response and provides a holistic view of receptor signalling
and ligand pharmacology.27 The biosensor uses long-wave-
length light for illumination of the biosensor but not the cells,
and non-invasively monitors the DMR in real time.
DMR assays
Three different types of DMR assays, persistent assay in
microplate, inhibitor washout assay in microplate, and
perfusion assay under microfluidics, were used to elucidate
the whole cell phenotypic efficacy of EGFR inhibitors. For
DMR assay in microplate, an inhibitor was added to and
incubated with the cells for 1 h and the cells were then
challenged with EGF in the presence of the inhibitor. The pre-
incubation step used was due to the slow cell uptake rate of
TKIs.
For inhibitor washout DMR assay in microplate an inhibitor
was added to and incubated with the cells for 1 h, followed by
washing out the free inhibitor in solution with the assay buffer
five times using a plate washer (Bio-Tek Microplate Washers
ELx405TM, Bio-Tek, Winooski, VT), and incubating with the
assay buffer for 1 h and finally stimulating with EGF.
For perfusion DMR assay under microfluidics the cells were
perfused sequentially with an inhibitor, then the assay buffer,
and finally EGF. The inlet holes of the microfluidic biosensor
device were connected to three independently operated
syringes using Tygon Ò tubing, so that continuous perfusion
of cells with three different solutions, one at a time, is possible
without introducing any abrupt changes of shear stress or
laminar flow perturbation inside the microfluidic chamber.
The flow rate was 1 ml min21 for all solutions to minimize the
effect of shear stress on cellular status.28,29
All real-time DMR signals were reported as a 2 min baseline
right before EGF stimulation followed by a real time EGF-
induced response. All DMR signals were obtained at 26 uC and
were background corrected. It is worth noting that the EGFR
activation in A431 under physiological condition gave rise to a
DMR similar to that obtained at room temperature.31 For DMR
assays in microplate, an averaged DMR response was obtained
from the cells within the scanning path.32 For DMR assay
under microfluidics an averaged response from the cells
located within the central area (0.2 6 2 mm) of a
biosensor.28,29 The assay buffer for all was 16 Hank’s
balanced salt solution, 20 mM Hepes, pH 7.1 (HBSS). All
studies were carried out with at least three replicates unless
specifically mentioned.
Data analysis
All experimental data were analysed by using GraphPad Prism
5.0 (GraphPad Software Inc., San Diego, CA, USA). The EC50
and IC50 values were obtained by fitting the dose DMR
response curves with nonlinear regression.
Results and discussion
We chose to study the whole cell efficacy of three EGFR
inhibitors, gefitinib, erlotinib and AG1478. These TKIs are
synthetic and quinazoline-derived small molecules that bind
to the intracellular tyrosine kinase domain of EGFR, and
inhibit EGF-induced receptor phosphorylation by competing
for the intracellular MgATP binding site. We characterized the
pharmacology of these TKIs in two native cell lines, A431 and
HT-29. A431 expresses a high amount of EGFR and a low level
of HER2,33 while HT-29 expresses moderate EGFR, a relatively
high amount of HER2, and a low level of erbB4.34,35 We chose
DMR assays under three distinct operational schemes19 to
assess the molecular mechanism of action of these TKIs
(Fig. 1). Persistent DMR assay in microplate probes the TKI
allosteric modulation of EGF binding and the inhibition of
receptor signaling at the whole cell level. Inhibitor washout
DMR assay examines the effect of cell uptake and retention of
these TKIs on receptor signaling. Perfusion DMR under
microfluidics examines the functional recovery of receptor
signaling after perfusion away both free and effluxed TKIs.
We first characterized the DMR of EGF in both A431 and
HT-29 cells. Results showed that in A431 cells, EGF of 32 nM
Fig. 1 Three distinct types of DMR assays. (a) Persistent DMR assay in microplate
wherein the inhibitor is introduced before EGF stimulation, but remains
throughout the assay. (b) Inhibitor washout DMR assay in microplate wherein
after cell uptake the free inhibitor in solution is washed out. (c) Perfusion DMR
assay under microfluidics wherein after cell uptake the free and effluxed
inhibitor is perfused away. For all three assays the EGF response is obtained by
monitoring cell responses in real time when EGF is always present once
introduced.



















































triggered a robust DMR consisting of three phases: an initial
increased DMR event (positive-DMR, P-DMR), a decayed DMR
event (negative-DMR, N-DMR) and another slowly increased
DMR event (recovery positive-DMR, RP-DMR) (Fig. 2a). As the
negative control, the cell response to the buffer only was also
included. Fitting the dose response curve with nonlinear
regression gave rise to an EC50 value that is a little sensitive to
the EGF treatment time. The EGF EC50 was found to be 1.12 ¡
0.09, 1.52 ¡ 0.10, and 0.48 ¡ 0.04 nM (n = 4) for the DMR at 3,
30 and 50 min post EGF stimulation, respectively (Fig. 2b).
Similarly, in HT-29 cells, EGF of 2 nM triggered a robust DMR
which also consists of three phases: an initial P-DMR, an
N-DMR and a RP-DMR (Fig. 2c). Compared to A431, the EGF
DMR in HT-29 is distinct in that the decayed N-DMR in HT-29
does not reach a negative value relative to the baseline, and the
kinetics for all three phases is slower, possibly due to the
different expression pattern of the receptors. The dose
response curves in HT-29 also yielded to a large degree an
assay time-insensitive EC50, which was 89.4 ¡ 7.1, 62.3 ¡ 5.8,
and 66.9 ¡ 5.2 pM (n = 4) for the DMR at 10, 30 and 80 min
post EGF stimulation, respectively. It is known that EGFR
activation triggers multiple pathways; distinct pathways have
different kinetics, and the EGF DMR represents an integration
of these pathways into a real time kinetic response. Our
previous pathway deconvolution studies have shown that for
the EGF DMR in A431, the early P-DMR is mostly due to
protein kinase C pathway, while the N-DMR is due to receptor
internalization and mostly cell detachment, and the RP-DMR
due to the re-attachment.36,37 This was confirmed by recent
studies using quartz crystal microbalance with dissipation
monitoring, a biosensor that is also sensitive to mass
redistribution.38,39 However, the exact cellular mechanism(s)
for the different DMR in HT-29 is mostly unknown.
Considering that each phase of the EGF DMR contains
information related to distinct pathways, we chose the above-
mentioned three time points to quantify the pharmacology of
the TKIs.
Next, we compared the inhibition profiles of three TKIs in
A431 under two different conditions: persistent treatment and
inhibitor washout. For both, the inhibitor was used to pretreat
the cells for 1 h, given that cell uptake requires time to reach
equilibrium.40 The washout period was set to be 1 h,
considering that the cells were sensitive to buffer washing
and took time (y30 min) to reach steady state for biosensor
measurement.19 Results showed that under the persistent
treatment all inhibitors dose-dependently inhibit the EGF
DMR (Fig. 3a,e,i). For the EGF responses at 30 and 50 min,
gefitinib gave rise to a clear biphasic modulation profile—it
initially increased their amplitudes (that is, being more
negative) followed by an inhibition (Fig. 3b); however, both
erlotinib and AG-148 led to a monophasic inhibition (Fig. 3f
and j, respectively). This is possibly due to the fact that
gefitinib can dose-dependently increase the binding affinity of
EGF to the receptor in A431, and/or probably by increasing the
numbers of EGFR dimers.33 Therefore, only until sufficiently
high doses are reached inside the cells gefitinib starts to
inhibit the EGF response.
Given that the inhibition curves of the EGF early DMR do
not seem lead to good nonlinear regression fit, we used the
late two events for IC50 determination. The apparent IC50
values to inhibit the EGF responses at 30 and 50 min,
respectively, was found to be 2.36 ¡ 0.21 and 2.86 ¡ 0.18 mM
(n = 4) for gefitinib; 1.94 ¡ 0.15 and 2.79 ¡ 0.24 mM (n = 4) for
erlotinib; and 0.42 ¡ 0.04 and 0.48 ¡ 0.03 mM (n = 4) for AG-
1478. These apparent IC50 values were generally much higher
than their corresponding in vitro binding affinities,21 but
consistent with many cell-based results.41
Unexpectedly, the inhibitor washout only had small impact
on the dose-dependent inhibition of all three inhibitors
(Fig. 3c,g,k). However, three noticeable differences were
observed for these dose inhibition curves (Fig. 3d,h,l). First,
all three inhibitors gave rise to a monophasic inhibition.
Second, the washout unexpectedly increased the potency of
gefitinib and AG-1478, but not erlotinib, to inhibit the
response at 30 min. The apparent IC50 values to inhibit the
EGF responses at 30 and 50 min, respectively, were found to be
0.80 ¡ 0.07 and 2.55 ¡ 0.23 mM (n = 4) for gefitinib; 2.37 ¡
0.18 and 2.60 ¡ 0.27 mM (n = 4) for erlotinib; and 0.13 ¡ 0.01
and 0.11 ¡ 0.01 mM (n = 4) for AG-1478. Third, the Hill slope
was less steep for all inhibitors under the washout condition
than that under persistent treatment condition. This suggests
that after the free inhibitors in solution are removed, the TKIs
taken up by cells mostly remain inside cells and continuously
suppress the EGFR signaling. Furthermore, the continuous
presence of free TKIs may be important for the enhanced
Fig. 2 The EGF DMR in A431 and HT-29. (a) The DMR of 32 nM EGF in A431 in
comparison with the negative control (the assay buffer, HBSS). (b) The DMR
amplitudes at 3, 30 and 50 min poststimulation as a function of EGF dose in
A431. (c) The DMR of 2 nM EGF in HT-29 in comparison with the negative
control (HBSS). (d) The DMR amplitudes at 10, 30 and 80 min poststimulation as
a function of EGF dose in HT-29. Data represents mean ¡ s.d. (n = 32, 4, 32, and
4 for a, b, c, and d, respectively).



















































binding affinity of EGF to the receptor, thus leading to the
need of high doses of TKIs to fully inhibit the receptor
signaling when the EGF concentration is fixed.
Next, we compared the inhibition profiles of three TKIs in
HT29 under persistent treatment and inhibitor washout
conditions. Results showed that under both conditions all
TKIs dose-dependently and mostly monotonically inhibited
the DMR responses of 2 nM EGF at 10 or 80 min; however, they
gave rise to a clear biphasic modulation profile of the EGF
response at 30 min poststimulation, an initial potentiation
followed by an inhibition, as the dose of all three TKIs
increases (Fig. 4). Again, this is possibly due to the increased
binding affinity of EGF to the receptors in the presence of
TKIs. Unlike A431, the EGF DMR modulation patterns by all
three TKIs were almost identical between the two different
assay formats. For persistent treatment, the apparent IC50
values to inhibit the EGF responses at 10 and 80 min,
respectively, were found to be about 7.6 and 7.5 mM (n = 4; only
the mean value given due to the high Hill slope) for gefitinib;
10.6 ¡ 0.9 and 11.7 ¡ 1.0 mM (n = 4) for erlotinib; and 0.48 ¡
0.04 and 0.34 ¡ 0.03 mM (n = 4) for AG-1478 (Fig. 4b,f,j). The
steepness of the dose inhibition curves was the greatest for
gefitinib with a Hill slope of 16 to 18, moderate for erlotinib
with a Hill slope of 3.2 to 3.9, and the smallest for AG-1478
with a Hill slope of 1.9 to 2.1. For TKI washout, the apparent
IC50 values to inhibit the EGF responses at 10 and 80 min,
respectively, were found to be about 8.6 ¡ 0.7 and 6.8 ¡ 0.5
mM (n = 4) for gefitinib; 16.0 and 15.8 mM (n = 4) for erlotinib;
and 0.91 ¡ 0.07 and 0.51 ¡ 0.04 mM (n = 4) for AG-1478
(Fig. 4d,h,l). The Hill slope was 3.0 and 4.5 for gefitinib, 12 and
26 for erlotinib, and 1.5 and 2.0 for AG-1478. Also noticeably,
but different from A431, was that for the EGF response at 10
and 80 min, all TKIs first slightly increased the signal followed
by inhibition, as their doses increase. The apparent IC50 and
Hill slope patterns of TKIs were distinct from A431, possibly
due to the different expression patterns of different EGFR
family members in the two cells. Nonetheless, the ability of
TKI pretreatment to block EGFR signaling after inhibitor
washout suggests that TKIs were taken up by cells and mostly
remain inside cells.
Fig. 3 Inhibition profiles of three TKIs in A431 under two different conditions. (a, e, i) The EGF DMR after 1 h pretreatment with gefitinib (a), erlotinib (e) and AG-1478
(i) at different doses. (b, f, j) The EGF DMR amplitudes at 3, 30 and 50 min poststimulation as a function of the dose of gefitinib (b), erlotinib (f) and AG-1478 (j) under
persistent treatment condition. (c, g, k) The DMR of 32 nM after pretreatment with gefitinib (c), erlotinib (g) and AG-1478 (k) at different doses for one hour followed
by washout and one hour buffer incubation. (d, h, l) The EGF DMR amplitudes at 3, 30 and 50 min poststimulation as a function of the dose of gefitinib (d), erlotinib
(h) and AG-1478 (l) under inhibitor washout condition. The EGF concentration was 32 nM for all. Data represents mean ¡ s.d. (n = 4 for all).



















































Lastly, we examined the effect of TKI removal by perfusion
using DMR assay under microfluidics. This assay permits
complete removal of both free and effluxed inhibitors. The
EGF response in the presence of an equal amount of an
inhibitor after the initial perfusion with the inhibitor was used
as a positive control; this condition is similar to the persistent
DMR in microplate, except that there is a slow and continuous
perfusion throughout the assay. Results showed that in A431,
an EGF of 32 nM triggered a DMR similar to that obtained in
microplate, suggesting that the continuous perfusion at the
slow rate used had only a small effect on the EGFR signaling in
this cell line (Fig. 5a). The persistent perfusion with 10 mM
gefitinib almost completely inhibited the EGF response, while
the cells responded to EGF with a small but noticeable DMR
when a perfusion step with the buffer was introduced between
the first TKI and the last EGF stimulation steps (Fig. 5a). The
EGF DMR was greater when the buffer perfusion step lasted
longer, suggesting that some intracellular inhibitors are
released and removed during the buffer perfusion step.
Almost identical patterns were observed for erlotinib
(Fig. 5b). In contrast, the persistent perfusion with sotalol
completely inhibited the isoprotenerol DMR; but the buffer
perfusion of 10 min was found to be sufficient to abolish the
antagonistic effect of sotalol on the isoprotenerol-induced
DMR (Fig. 5c). The isoprotenerol DMR in A431 has been
shown to be due to the activation of endogenous b2-adrenergic
receptor, a prototypic G protein-coupled receptor (GPCR).42,43
Sotalol is a known b-blocker.44 This suggests that sotalol is a
reversible competitive antagonist with a rapid off rate for the
receptor. Unlike EGFR TKIs which bind to the intracellular
domain of the receptor after getting inside the cell first, most
GPCR antagonists bind to the site(s) located within the
transmembrane domains of the receptor directly from the
extracellular side.
In HT-29 cells, perfusion with 2 nM EGF triggered a
biphasic DMR that is somewhat distinct from that obtained in
microplate (comparing Fig. 5d with Fig. 2c), suggesting that
the continuous perfusion had a more pronounced impact on
the EGFR signaling in HT-29 cells than that in A431 cells. The
continuous perfusion with 10 mM gefitinib significantly
suppressed the EGF DMR, and the buffer perfusion clearly,
but not completely, reversed the inhibitory effect of gefitinib
Fig. 4 Inhibition profiles of three TKIs in HT29 under two different conditions. (a, e, i) The DMR of EGF after 1 h pretreatment with gefitinib (a), erlotinib (e) and AG-
1478 (i) at different doses. (b, f, j) The EGF DMR amplitudes at 10, 30 and 80 min poststimulation as a function of the dose of gefitinib (b), erlotinib (f) and AG-1478 (j)
under persistent treatment condition. (c, g, k) The DMR of 2 nM after pretreatment with gefitinib (c), erlotinib (g) and AG-1478 (k) at different doses for one hour
followed by washout and 1 h buffer incubation. (d, h, l) The EGF DMR amplitudes at 10, 30 and 80 min poststimulation as a function of the dose of gefitinib (d),
erlotinib (h) and AG-1478 (l) under inhibitor washout condition. The EGF concentration was 2 nM for all. Data represents mean ¡ s.d. (n = 4 for all).



















































on the EGF DMR (Fig. 5d). A similar pattern was observed for
erlotinib (Fig. 5e). As a control, the persistent perfusion with
10 mM CID 2745687 completely suppressed the DMR signal of
1 mM zaprinast in HT-29, when the buffer perfusion of 10 min
was sufficient to eliminate the inhibitory effect of CID 2745687
(Fig. 5f). CID 2745687 is a known GPR35 antagonist,45,46 and
zaprinast is a known GPR35 agonist.47 The zaprinast DMR in
HT-29 was previously shown to be due to the activation of
endogenous GPR35.48,49 This result suggests that CID 2745687
is a reversible antagonist with a fast off rate for the GPR35.
The whole cell phenotypic pharmacology of EGFR TKIs is
complicated by several factors (Fig. 6). First, EGFR behaves as
an allosteric protein in that the agonists bind to the
extracellular domain of the receptor and result in the receptor
dimerization, while the TKIs bind to the intracellular protein
tyrosine kinase domain of the receptor. The binding of TKIs
has been shown to alter the binding characteristics of EGF to
the EGFR in A431.33 Therefore, the inhibition profile of the
whole cell EGF response by these TKIs reflect an allosteric,
rather than directly competitive, effect between the two types
of ligands. This may at least partially explain the differences in
the Hill slopes of the inhibition profiles observed, as well as
the biphasic inhibition profiles of some TKIs under some
conditions. Second, the expression pattern of EGFR family
members in the two cell lines is different.33–35 The EGF-
induced heterodimerization may contribute to the difference
in both the EGF DMR and the TKI inhibition profiles. Third,
unlike GPCR ligands which bind to the receptor from the
extracellular side, the TKIs need be taken up by the cells first.
Cell uptake of TKIs is a relatively slow process via both active
and passive processes, taking over 30 min to reach a plateau in
A431 and other cells.40,50 The intracellular TKI concentration
is dependent on the amount of TKIs added and the time of cell
uptake, but is generally higher than that in the assay solution.
This obviously impacts the characteristics of the TKI inhibi-
tion curves. Fourth, the retention of TKIs inside the cells once
Fig. 5 Inhibition profiles of TKIs in A431 and HT29 under microfluidic conditions. (a–c) A431 cells; (d–f) HT-29 cells. (a) The DMR of 32 nM EGF in A431 after perfusion
with 10 mM gefitinib for 1 h and then the buffer for 10 or 60 min. (b) The DMR of 32 nM EGF in A431 after perfusion with 10 mM erlotinib for 1 h and then the buffer
for 10 or 60 min. (c) The DMR of 10 nM isoprotenerol in A431 after perfusion with 10 mM sotalol for 1 h and then the buffer for 10 min. (d) The DMR of 2 nM EGF in
HT-29 after perfusion with 10 mM gefitinib for 1 h and then the buffer for 10 or 60 min. (e) The DMR of 2 nM EGF in HT-29 after perfusion with 10 mM erlotinib for 1 h
and then the buffer for 10 or 60 min. (f) The DMR of 1 mM zaprinast in HT-29 after perfusion with 10 mM CID 2745687 for 1 h and then the buffer for 10 min. The
‘‘control’’ in all graphs is the DMR of the respective agonist obtained in the cells without pretreatment with any inhibitors. The ‘‘persistent’’ in all graphs means that
the DMR of the respective agonist was obtained after perfusion with the corresponding antagonist for 1 h followed by the mixture of the agonist and equal
concentration of the antagonist. Data represents mean ¡ s.d. (n = 3 for all).
Fig. 6 The factors influencing the whole cell phenotypic efficacy of TKIs. The
intracellular pool of TKIs is a function of both cell uptake and effluxing. Free TKIs
in solution can be taken up by the cells via both passive (minor) and active
(major) processes. The intracellular TKIs can be pumped out through
transporters. The binding of TKIs to the tyrosine kinase domain can alter the
binding affinity and kinetics of the EGF to the receptor. The TKI binding kinetics,
in particular the off rate can also influence the efficacy.



















































taken up also contributes to the overall efficacy of TKIs to
block EGFR signaling. Kinase inhibitors are known to generate
an ‘‘echo’’ effect when the cells are first exposed to the
inhibitor and then washed to remove the free inhibitor in
solution,51 suggesting the importance of cell retention on the
efficacy of TKIs in cells. The cell retention of TKIs is a function
of cell uptake and effluxing. The TKI effluxing can be
accomplished through efflux transporter such as ABCG2. All
three TKIs tested are ABCG2 substrates; the overexpression of
ABCG2 has been shown to protect A431 cells from death after
gefitinib through a mechanism involving pumping the TKIs
out.52,53 Furthermore, gefitinib at high doses is also an ABCG2
inhibitor. The native A431 cells express little ABCG2;52
however, the native HT-29 expresses high amount of
ABCG2.54 This is consistent with our data showing that the
buffer perfusion led to faster recovery of the EGF DMR in HT-
29 than that in A431 cells; the buffer perfusion is more
effective to cause the recovery of the EGF signal in HT-29 cells
than the inhibitor washout in plates; and the potency of three
TKIs is generally higher in A431 than HT-29 cells. Lastly, we
cannot rule out the impact of the binding kinetics on the
whole cell inhibition profiles of TKIs. All three TKIs tested are
reversible inhibitors for EGFR but with distinct affinity and
kinetics.21 The TKI with a slower off rate may display a higher
efficacy to block the EGFR signaling. However, considering the
rapid off rate of the three TKIs tested21 as well as the slow cell
uptake40,50, both on and off rates are obviously less important
than the cell uptake and retention.55
Conclusions
We have examined the label-free whole cell phenotypic efficacy
of three EGFR inhibitors to block the receptor signaling in two
native cell lines. DMR assays under three distinct operational
schemes revealed that the drug uptake and retention seem
have a dominating role in determining their whole cell
efficacy. DMR assays, in particular those under microfluidics,
may offer a unique means to determine the influence of efflux
transporter on the efficacy of EGFR and other kinase
inhibitors, and to probe the transporter-related drug resis-
tance.
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